Short Interest in ITeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.0%
Short Interest in ITeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.0%
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,460,000 shares, a growth of 5.0% from the December 31st total of 1,390,000 shares. Based on an average daily volume of 328,200 shares, the days-to-cover ratio is currently 4.4 days. Currently, 5.1% of the shares of the stock are short sold.
iTeos Therapeutics, Inc.(纳斯达克股票代码:ITOS — Get Rating)在1月份的空头利率大幅增长。截至1月15日,空头利率共计146万股,较12月31日的139万股增长了5.0%。根据328,200股的平均每日成交量,目前天数与覆盖率为4.4天。目前,该股有5.1%的股票被卖空。
Institutional Trading of iTeos Therapeutics
iTeOS Therapeutics 的
A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in iTeos Therapeutics by 16.0% in the 3rd quarter. BlackRock Inc. now owns 4,317,157 shares of the company's stock worth $82,241,000 after acquiring an additional 595,920 shares during the last quarter. State Street Corp increased its stake in iTeos Therapeutics by 44.8% in the 2nd quarter. State Street Corp now owns 2,478,332 shares of the company's stock worth $51,054,000 after acquiring an additional 766,441 shares during the last quarter. Vanguard Group Inc. increased its position in shares of iTeos Therapeutics by 7.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,751,100 shares of the company's stock valued at $33,358,000 after purchasing an additional 121,514 shares during the last quarter. Candriam S.C.A. increased its position in shares of iTeos Therapeutics by 15.2% during the 2nd quarter. Candriam S.C.A. now owns 787,651 shares of the company's stock valued at $16,225,000 after purchasing an additional 103,839 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of iTeos Therapeutics by 146.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 559,299 shares of the company's stock valued at $11,522,000 after purchasing an additional 332,625 shares during the last quarter.
许多大型投资者最近增加了或减少了在该公司的股份。贝莱德公司在第三季度将其在iTeOS Therapeutics的股份增加了16.0%。贝莱德公司在上个季度又收购了595,920股股票后,现在拥有该公司4,317,157股股票,价值82,241,000美元。State Street Corp在第二季度将其在iTeOS Therapeutics的股份增加了44.8%。State Street Corp在上个季度又收购了766,441股股票后,现在拥有该公司股票的2478,332股,价值51,054,000美元。Vanguard Group Inc.在第三季度将其在iTeOS Therapeutics的股票头寸增加了7.5%。Vanguard Group Inc.在上个季度又购买了121,514股股票后,现在拥有该公司1,751,100股股票,价值33,35.8万美元。Candriam S.C.A. 在第二季度将其在iTeOS Therapeutics的股票头寸增加了15.2%。Candriam S.C.A. 在上个季度又购买了103,839股股票后,现在拥有该公司787,651股股票,价值16,225,000美元。最后,摩根大通在第二季度将其在iTeOS Therapeutics的股票头寸增加了146.7%。摩根大通在上个季度又购买了332,625股股票后,现在拥有该公司559,299股股票,价值11,522,000美元。
iTeos Therapeutics Trading Up 2.1 %
iTeos Therapeutics 交易价格上涨
ITOS traded up $0.43 on Tuesday, hitting $20.82. 66,953 shares of the company's stock traded hands, compared to its average volume of 326,153. The company's 50 day simple moving average is $19.83 and its 200-day simple moving average is $20.97. The firm has a market cap of $740.78 million, a price-to-earnings ratio of 2.96 and a beta of 1.38. iTeos Therapeutics has a one year low of $16.21 and a one year high of $37.88.
ITOS周二上涨0.43美元,至20.82美元。该公司股票交易量为66,953股,而平均交易量为326,153股。该公司的50天简单移动平均线为19.83美元,其200天简单移动平均线为20.97美元。该公司的市值为7.4078亿美元,市盈率为2.96,beta为1.38。iTeos Therapeutics创下了16.21美元的一年低点,为37.88美元。
iTeos Therapeutics Company Profile
iTeos Therapeutic
(Get Rating)
(获取评分)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Iteos Therapeutics, Inc是一家临床阶段的生物制药公司,从事患者免疫肿瘤疗法的发现和开发。该公司的产品线包括 inupadenant,一种正在进行第 2 期临床试验的腺苷 A2AR 拮抗剂的小分子拮抗剂;以及 EOS-448,一种具有 Ig 和 ITIM 结构域的 TIGIT 或 T 细胞免疫受体的拮抗剂,正处于 1/2 期临床试验,用于与 Fc 伽玛受体或 Fc?R 激活树突状细胞和巨噬细胞,促进抗体依赖性细胞毒性或 ADCC 活性。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on iTeos Therapeutics (ITOS)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
- 免费获取 StockNews.com 关于 iTEOS Therapeutics (ITOS) 的研究报告的副本
- Verizon、Charter在过去一个月中呈上升趋势:他们现在买了吗?
- 股息之王 Sysco:逢低买入
- Genius集团股票上涨1,600%是否合理?
- 经过进一步审查,投资者喜欢埃克森美孚的收益
- 卡特彼勒会挖掘另一个买入机会吗?
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 iTeOS Therapeutics 每日的新闻和评 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收iTeOS Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。